Following on from information provided to NICE by the company in January 2020, the appraisal of Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 2714 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 November 2022 | Discontinued. Following on from information provided to NICE by the company in January 2020, the appraisal of Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 19 May 2021 | Expected publication |
| 14 February 2020 | The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714] The company have advised that they will not be seeking regulatory approval for nivolumab for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred, NICE will continue to monitor the situation and update interested parties if or when the situation changes. |
| 10 January 2020 | In progress. Referred October 28 2019 |
| 14 February 0202 | Suspended. Topic is now suspended |
For further information on our processes and methods, please see our CHTE processes and methods manual